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CLINICAL GUIDELINESThe role of surgical cytoreduction in the treatment of
malignant pleural mesothelioma: Meeting summary of the
International Mesothelioma Interest Group Congress, September 11-
14, 2012,
Boston, MassValerie Rusch, MD,a Elizabeth H. Baldini, MD, MPH,b Raphael Bueno, MD,c Marc De Perrot, MD,d
RajaFlores,MD,e SeikiHasegawa,MD,fWalterKlepetko,MD,gLeeKrug,MD,hLo€ıc Lang-Lazdunski,MD,
PhD, FRCS (Eng),i Harvey Pass, MD,j Walter Weder, MD,k and David J. Sugarbaker, MD,c on behalf of the
participants in the 2012 International Mesothelioma Interest Group CongressThe treatment of all solid tumors, including malignant
pleural mesothelioma (MPM), is dependent on (1) macro-
scopic complete resection and (2) treatment of micrometa-
static disease. The role of surgery in the treatment of MPM
has been the subject of debate after the recent publication of
the Mesothelioma and Radical Surgery (MARS) I trial.1
The International Mesothelioma Interest Group (IMIG)
met from September 11 through 14, 2012, in Boston,
Mass. During this meeting, more than 500 participants rep-
resenting all the involved specialty groups met in multiple
comprehensive sessions to review, critique, and extend the
state of knowledge regarding the role of surgery, including
both extended pleurectomy/decortication (P/D) and extrap-
leural pneumonectomy (EPP), in the treatment of MPM.
Some of the deficiencies of the MARS I trial, which was
published a year ago in Lancet Oncology, were discussed in
multiple sessions of the IMIG meeting. The editorial that
accompanied the publication articulated numerous short-
comings of the trial.2 TheMARS I trial was designed as a pi-
lot feasibility trial, the result of which was negative in that it
failed to demonstrate the feasibility of randomly allocating
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The Journal of Thoracic and Capublication contained an analysis of tertiary end points, in-
cluding survival, which was based on the small pilot cohort,
representing fewer than 10% of the required sample size for
an adequately powered between-arm comparison as pub-
lished by the MARS trialists. Protocol compliance was
also poor in that 6 of 26 patients in the no EPP group under-
went off-protocol surgery, whereas only 16 of 24 patients in
the EPP group actually underwent EPP.
Quality control of the surgery in theMARS trial, if under-
taken, was not reported. Intent-to-treat morbidity (11/24;
46%) and mortality (3/24; 13%), and more strikingly,
EPP-associated morbidity (11/16; 69%) and mortality
(3/16; 19%), were much higher than reported in the litera-
ture. The chemotherapy regimens appliedwere uncontrolled.
Neither final histologic type nor disease stage was reported
for the patients who underwent surgery, leaving an open
question as towhether these patients, who demonstrated sur-
vival inferior to most previous reports, may have had dispro-
portionate N2 or nonepithelial disease. Conversely, the
reported 19-month median survival among chemotherapy-
only (no EPP) patients was clearly anomalous when
compared with a vast prospective literature. The long-term
outcome of the study cohort remains unknown, because the
overall survival analysiswas truncated at 18months,whereas
the quality of life data were reported to 24months. These de-
ficiencies make drawing any conclusions from MARS I re-
garding the therapeutic efficacy of EPP impossible.
The patterns of failure in MPM were reaffirmed at the
2012 IMIG meeting. Dr Elizabeth H. Baldini, in reference
to her previous work, presented a contemporary group of
patients and demonstrated essentially the same distribution
of recurrence as originally reported, which is primarily lo-
cal.3 Six institutional series from the US, Europe, and Japan
involving macroscopic complete resection by EPP or P/D in
the setting of multimodality treatment of MPM were pre-
sented at the meeting.4-9 These reports were discussed in de-
tail in light of previous literature to date. Median survival
ranged from 25 to 37 months for patients with epithelial dis-
ease and negative extrapleural lymph nodes. Operativemor-
tality ranged from 0% to 2%.rdiovascular Surgery c Volume 145, Number 4 909
Clinical Guidelines Rusch et alOn behalf of the International Association for the Study of
LungCancer (IASLC), DrValerie Rusch presented a prelim-
inary analysis of the IASLC staging project, which has since
been published in the November 2012 issue of the Journal of
Thoracic Oncology.10 In the IASLC worldwide registry of
patients with all stages of epithelial MPM, the analysis
showed 19-month median survival among 1359 patients un-
dergoing surgical resection (P/D or EPP).Moreover, patients
undergoing EPP for early-stage disease demonstrated
survival superior to that of all other subgroups, a median of
40 months. On the basis of the current literature and the
IASLC report, it was concluded by IMIG members that
surgery, whether P/D or EPP, with the goal of obtaining
a macroscopic complete resection should be performed in
the multimodality treatment of MPM. In particular, it was
agreed that the type of cytoreductive procedure should be se-
lected on the basis of disease distribution, institutional
experience, and surgeon preference and experience. Further-
more, itwas collectively decided that these operations should
be performed by surgeons who have achieved morbidity and
mortality within the scope of the current literature.
After much discussion in multiple forums and settings with
surgeons, medical oncologists, radiation oncologists, epide-
miologists, and basic scientists, the attendees of the 2012
IMIG meeting reached agreement on the following points:
 Surgicalmacroscopic complete resection andcontrol ofmi-
crometastatic disease play a vital role in the multimodality
therapy ofMPM, as is the case for other solidmalignancies.
 Surgical cytoreduction is indicated when macroscopic
complete resection is deemed achievable.
 The type of surgery (EPP or P/D) depends on clinical fac-
tors and on individual surgical judgment and expertise.
 All patients with the diagnosis of MPM should be ini-
tially evaluated in a multidisciplinary setting, including
medical oncology, radiation oncology, and surgery.
 Clinical staging (lymph node sampling, positron emis-
sion tomography, magnetic resonance imaging) should
be performed before therapy.
 The histologic subtype should be identified by tissue
biopsy before initiation of therapy.910 The Journal of Thoracic and Cardiovascular SurgReferences
1. Treasure T, Lang-Lazdunski L, Waller D, Bliss JM, Tan C, Entwisle J, et al. Ex-
tra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients
with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma
and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol.
2011;12:763-72.
2. Weder W, Stahel RA, Baas P, Dafni U, de Perrot M, McCaughan BC, et al. The
MARS feasibility trial: conclusions not supported by data. Lancet Oncol. 2011;
12:1093-4; author reply 1094-5.
3. Goodman BM, Gill RR, Winfrey O, Richards WG, Chen AB, Kozono DE, et al.
Patterns of recurrence following extrapleural pneumonectomy (EPP) for
malignant pleural mesothelioma (MPM). In: 11th International
Conference of the International Mesothelioma Interest Group abstract book.
Boston: iMig; 2012. Available at: http://www.imig2012.org/documents/
iMig2012_AbstractBook_vF_Sept10_REV.pdf. Abstract IIIA.2.
4. B€ol€ukbas S, Eberlein M, Kudelin N, Fisseler-Eckhoff A, Schirren J. Long-term
outcome after radical pleurectomy followed by chemoradiation for malignant
pleural mesothelioma: a 10-year single center experience. In: 11th International
Conference of the International Mesothelioma Interest Group abstract book.
Boston: iMig; 2012. Available at: http://www.imig2012.org/documents/
iMig2012_AbstractBook_vF_Sept10_REV.pdf. Abstract IIB.2.
5. Sugarbaker DJ, Dasilva M, Supko J, Winfrey O, Eisen H, Barlow J, et al. Pro-
spective phase I trial of extrapleural pneumonectomy or pleurectomy/decortica-
tion, intrathoracic/intraperitoneal hyperthermic [HIOC] cisplatin and
gemcitabine with intravenous amifostine and sodium thiosulfate cytoprotection
for patients with resectable malignant pleural mesothelioma. In: 11th Interna-
tional Conference of the International Mesothelioma Interest Group abstract
book. Boston: iMig; 2012. Available at: http://www.imig2012.org/documents/
iMig2012_AbstractBook_vF_Sept10_REV.pdf. Abstract IIB.4.
6. Friedberg J, Culligan MJ, Mick R, Hahn SM, Stevenson J, Alley E, et al. Radical
pleurectomy and intraoperative porfimer sodium photodynamic therapy for
malignant pleural mesothelioma. In: 11th International Conference of the
International Mesothelioma Interest Group abstract book. Boston: iMig; 2012.
Available at: http://www.imig2012.org/documents/iMig2012_AbstractBook_
vF_Sept10_REV.pdf. Abstract IIIA.4.
7. CaleA,Qadri S, CowenM,WieczorekA, LindMJ, et al. Is there life afterMARS?
Does extrapleural pneumonectomy still have a role in the management of malig-
nant pleural mesothelioma—a 13 years single centre experience. In: 11th Interna-
tional Conference of the International Mesothelioma Interest Group abstract
book. Boston: iMig; 2012. Available at: http://www.imig2012.org/documents/
iMig2012_AbstractBook_vF_Sept10_REV.pdf. Abstract P1.01.
8. Hasegawa S, Tanaka F, Kondo N, Okumura Y, Matsumoto S, Takuwa T, et al.
Outcome of consecutive 61 cases of intent-to-treat with extrapleural pneumonec-
tomy for resectable malignant pleural mesothelioma. In: 11th International Con-
ference of the International Mesothelioma Interest Group abstract book. Boston:
iMig; 2012. Available at: http://www.imig2012.org/documents/iMig2012_
AbstractBook_vF_Sept10_REV.pdf. Abstract P1.05.
9. Bille’ A, Okiror L, Spicer J, Steele JP, Landau D, Taylor H, et al. Pleurectomy/
decortication, hyperthermic pleural lavage with povidone-iodine followed by ad-
juvant chemotherapy: survival analysis in 65 consecutive patients. In: 11th Inter-
national Conference of the International Mesothelioma Interest Group abstract
book. Boston: iMig; 2012. Available at: http://www.imig2012.org/documents/
iMig2012_AbstractBook_vF_Sept10_REV.pdf. Abstract P3.18.
10. Rusch VW, Giroux D, Kennedy C, et al. Initial analysis of the International
Association for the Study of Lung Cancer mesothelioma database. J Thorac
Oncol. 2012;7:1631-9.ery c April 2013
